Zura Bio Limited Class A Ordinary Shares Market Cap ($243.84 Million)
Market Cap & Net Worth: Zura Bio Limited Class A Ordinary Shares (ZURA)
Zura Bio Limited Class A Ordinary Shares market cap. Zura Bio Limited Class A Ordinary Shares (NASDAQ:ZURA) has a market capitalization of $243.84 Million ($243.84 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15534 globally and #3698 in its home market, demonstrating a 12.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zura Bio Limited Class A Ordinary Shares's stock price $3.99 by its total outstanding shares 65023308 (65.02 Million). Also see Zura Bio Limited Class A Ordinary Shares cash flow conversion for how efficiently the company converts equity into cash flow.
Zura Bio Limited Class A Ordinary Shares Market Cap History (2023–2026)
Zura Bio Limited Class A Ordinary Shares market cap history from 2023 to 2026. Data shows change from $303.66 Million to $259.44 Million (-17.90% CAGR). Check Zura Bio Limited Class A Ordinary Shares stock quote for real-time trading data and today's change.
Index Memberships
Zura Bio Limited Class A Ordinary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #412 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1515 of 3165 |
Weight: Zura Bio Limited Class A Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zura Bio Limited Class A Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zura Bio Limited Class A Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ZURA shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ZURA by Market Capitalization
Companies near Zura Bio Limited Class A Ordinary Shares in the global market cap rankings as of November 5, 2026. Also see ZURA current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Zura Bio Limited Class A Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Zura Bio Limited Class A Ordinary Shares (2023–2026)
Market capitalization of Zura Bio Limited Class A Ordinary Shares from 2023 to today. Between 2023 and today, Zura Bio Limited Class A Ordinary Shares's market cap moved from $303.66 Million to $ 259.44 Million, with a yearly change of -17.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $259.44 Million | -23.85% |
| 2025 | $340.72 Million | +109.60% |
| 2024 | $162.56 Million | -46.47% |
| 2023 | $303.66 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Zura Bio Limited Class A Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $243.84 Million USD |
| MoneyControl | $243.84 Million USD |
| MarketWatch | $243.84 Million USD |
| marketcap.company | $243.84 Million USD |
| Reuters | $243.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more